BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
BriaCell Therapeutics Corp.
Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 9, 2026
$3.38−0.02 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $24.51M
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Apr 30, 2026
BriaCell Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in BriaCell Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.